Product
Five things for pharma marketers to know: Thursday, September 24, 2015
September 24, 2015Mylan's marketing of EpiPen raises questions about price; the number of drugs approved through expedited pathways is rising; new combo of old drugs may work for Alzheimer's patients
Five things for pharma marketers to know: Friday, September 4, 2015
September 04, 2015Longer-term use of AstraZeneca's Brilinta approved; Google streamlines health-related searches; Zarxio's price is higher than expected
Merck's anacetrapib has curiously strong effect on lipids
November 18, 2010Researchers said a new kind of cholesterol-modifying drug from Merck demonstrated remarkably strong LDL-lowering and HDL-raising effects, and appeared safe from a cardiovascular standpoint, stoking doctors' optimism that it could reach market.
Xarelto proves itself against warfarin
November 16, 2010Phase III data reported yesterday at the AHA Meeting in Chicago showed that new blood thinner Xarelto (rivaroxaban) stacks up well against warfarin in preventing strokes in patients with atrial fibrillation.
In Coumadin banter, lessons for marketers of new blood thinners
October 27, 2010A love-hate relationship for Coumadin (warfarin) is playing out online, say authors of a new report that may offer lessons for marketers of new blood-thinning products.
Watson beefs up women's health biz, adds reps
July 13, 2010Generics and specialty pharma Watson acquired a progesterone gel, marketed as Crinone and Prochieve, and added roughly 19 reps to its women's health sales force. Watson now employs close to 400 reps, according to Charlie Mayr, a company spokesperson.
Kowa's US CEO says new statin holds appeal for untreated patients
June 24, 2010To those who believe we have everything we need in the lipid-lowering world, Ben Stakely, Kowa Pharmaceuticals America (KPA) CEO and president, has one thing to say: "I would argue with you."
What's behind Humira's bullish forecast?
May 04, 2010A report predicting that Humira will become the world's biggest product in two years' time generated positive news for the Abbott Labs arthritis drug. Several factors are driving the bullish forecast.
Sanofi, Cegedim launch mobile CRM for managed markets
June 08, 2009Sanofi-Aventis partnered with Cegedim Dendrite to launch a CRM mobile platform for its managed market managers. The three-year agreement spans 28 countries, including the US, France and Japan.
Last chance to grab glory
June 04, 2009If you still haven't entered the MM&M Awards 2009, then you'd better move fast--today (June 5) is the final deadline for submissions.
Abbott, AZ extend co-promotion to Trilipix
June 04, 2009AstraZeneca will help Abbott reach more physicians with its Trilipix (fenofibric acid) drug, a cholesterol product approved by FDA last December. The companies also filed an NDA for Certriad, a Trilipix/Crestor combination drug.
GSK to co-promote Shire's Vyvanse
March 31, 2009GlaxoSmithKline will partner with Shire to co-promote Vyvanse, Shire's Adderall follow-on ADHD drug. The three-year deal will double the brand's sales force, with 600 GSK reps targeting primary care physicians and specialists, the companies announced today.
MPR rolls out revamped website
January 20, 2009Monthly Prescribing Reference (MPR) has relaunched its website with a number of enhancements to functionality and design, as well as a new, easier-to-remember URL, www.eMPR.com.
Allergan to launch eyelash enhancer
January 14, 2009Allergan is gearing up for the launch of Latisse, the first FDA-approved cosmetic eyelash enhancer, with a website and consumer ads in development.
New study results strengthen hormone therapy, cancer link
December 15, 2008Results from a large national study may have put the nail in the coffin of hormone replacement therapy (HRT) treatments, the Associated Press reported Saturday.
J&J Rx drug sales flat, consumer and devices up
October 14, 2008J&J flaunted the benefits of its diversified and globalized business portfolio today, reporting respectable third-quarter results despite static worldwide pharmaceutical sales of $6.1 billion.
Amgen to unbundle anemia medications
August 29, 2008Amgen announced plans to restructure its sales practices for Aranesp, a anemia drug used primarily for chemotherapy patients
Teva in $7.4 billion Barr buy
July 18, 2008Teva is buying Montvale, NJ-based Barr Pharmaceuticals for $7.4 billion and will take on debt of $1.5 billion.
Product news
May 20, 2008Bayer HealthCare Pharmaceuticals announced that a reformulation of the liquid Leukine (sargramostim) has been approved by FDA and is now available for patients and physicians in the US.
Product news
March 25, 2008Canadian regulators have approved Novartis' Diovan (valsartan) to treat chronic heart failure in patients who cannot tolerate angiotensin-converting-enzyme (ACE) inhibitors, a common type of heart failure therapy.
Sudler & Hennessey named global AOR for developmental arthritis med
March 21, 2008Sudler & Hennessey (S&H) has been selected by AstraZeneca as the global agency partner of record for the developmental arthritis treatment PN400.
Product news
March 20, 2008Cephalon announced that the FDA has approved Treanda (bendamustine hydrochloride) for injection for the treatment of patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow disease.
Product news
March 18, 2008Hawthorn Pharmaceuticals announced the FDA approval of the company's Granisol (granisetron HCl) oral solution. Granisol is an oral solution for the prevention of nausea and vomiting associated with cancer therapy.
Endo, Novartis begin Voltaren gel licensing deal
March 13, 2008Endo Pharmaceuticals has entered into a licensing agreement with Novartis to obtain the exclusive US marketing rights for the prescription medicine Voltaren Gel (diclofenac sodium topical gel) 1%.
Product news
March 04, 2008The FDA approved Wyeth's Pristiq (desvenlafaxine) to treat adult patients with major depressive disorder. Wyeth expects to begin shipping Pristiq to wholesalers beginning in the second quarter of 2008.
Product news
February 28, 2008The FDA approved AstraZeneca's Nexium (esomeprazole magnesium) for short-term use in children ages one -11 years for the treatment of gastroesophageal reflux disease (GERD).
Product news
February 26, 2008Sciele Pharma expaned its alliance with Sanofi-Aventis with a new exclusive, three-year agreement to market Allegra orally disintegrating tablets (ODT) and Allegra oral suspension in the pediatric market in the US.
Product news
February 21, 2008Eli Lilly announced the launch of KwikPen, a new insulin pen prefilled with Humalog (insulin lispro injection).
Product news
February 19, 2008The FDA has approved UCB and Sanofi-Aventis' NDA for Xyzal (levocetirizine dihydrochloride) 0.5 mg/ml oral solution, a prescription antihistamine indicated for the relief of symptoms associated with indoor and outdoor allergies, as well as the treatment of chronic idiopathic urticaria.
Product news
February 14, 2008Bentley Pharmaceuticals announced its European subsidiaries have received approvals to market their omeprazole capsule products, through their licensees, in various territories in Europe.
MM&M Articles
- McCann Health forms new global consultancy
- Alexion uses superheroes, social media to raise rare-disease awareness
- Five things for pharma marketers to know: Tuesday, September 20, 2016
- Five things for pharma marketers to know: Wednesday, September 21, 2016
- Five things for pharma marketers to know: Monday, September 19, 2016
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- When it comes to professional ads, print makes its comeback
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- The FDA approves Amgen's biosimilar version of Humira
- Five things for pharma marketers to know: Friday, September 23, 2016
- Five things for pharma marketers to know: Thursday, September 22, 2016
- Drug Pricing Will Be a Key Issue, Whether Clinton or Trump Win the Election
- The Michael J. Fox Foundation uses Facebook to recruit Ashkenazi Jews for Parkinson's study
